Toutes les photos(1)

Documents

1269447

USP

Fenofibrate

Name: Fenofibrate
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₂₀H₂₁ClO₄

Numéro CAS:

49562-28-9

Poids moléculaire :

360.83

Numéro MDL:

MFCD00133314

Code UNSPSC :

41116107

ID de substance PubChem :

329749836

Nomenclature NACRES :

NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fenofibrate

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2

InChI

1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

Clé InChI

YMTINGFKWWXKFG-UHFFFAOYSA-N

Informations sur le gène

human ... PPARA(5465)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Fenofibrate Capsules
Fenofibrate Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

F0048005

Fenofibrate impurity A, European Pharmacopoeia (EP) Reference Standard

1269607

F0048010

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard

1269629

1269618

F0048035

Fenofibrate impurity G, European Pharmacopoeia (EP) Reference Standard

1133558

Choline Fenofibrate, United States Pharmacopeia (USP) Reference Standard

PHR2864

Pictogrammes

GHS08

Mention d'avertissement

Warning

Mentions de danger

H373

Conseils de prudence

P260 - P314 - P501

Classification des risques

STOT RE 2 Oral

Organes cibles

Liver

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

Supelco

90568

Fenofibric acid

Sigma-Aldrich

B7273

Bezafibrate

Pleiotropic actions of fenofibrate on the heart.

Pitchai Balakumar et al.

Pharmacological research, 63(1), 8-12 (2010-11-26)

Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced

Role of the PPAR-α agonist fenofibrate in severe pediatric burn.

Itoro E Elijah et al.

Burns : journal of the International Society for Burn Injuries, 38(4), 481-486 (2012-01-10)

Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric

Effects of fenofibric acid on diabetic macular edema: the MacuFen study.

Pascale Massin et al.

Ophthalmic epidemiology, 21(5), 307-317 (2014-08-19)

Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not

Fenofibrate: a review of its use in dyslipidaemia.

Kate McKeage et al.

Drugs, 71(14), 1917-1946 (2011-09-29)

Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-α. Fenofibrate

Sox17 regulates liver lipid metabolism and adaptation to fasting.

Samuel Rommelaere et al.

PloS one, 9(8), e104925-e104925 (2014-08-21)

Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique